⌘K

07:00:00·59d

PRReleasevia Quantisnow

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ByQuantisnow·Wall Street's wire, on your screen.

CGEM· Cullinan Therapeutics Inc.

Health Care

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Quantisnow